Sourcebio Share Discussion Threads

[jacks13] 09/11/2022 14:47

The tender process is unlikely to mop up all of the shares held by the untouchables (us), so how does the company then proceed to tidy up the register and prune out the stragglers? Anyone know?

[mike_miikke] 09/11/2022 14:04

Interesting. Thank you for explaining your thoughts on this

[supernumerary] 09/11/2022 12:53

Very little - too many of the shares are in private hands. Run for the benefit of insiders not the rest of us. Currently at ~107 rather than the proposed 115, a difference that would have been arbitraged away if traders thought there was a serious prospect of either a rival bid, or that the 115 was nailed on. They could still come back with say 105 claiming they couldn't get funding...

[mike_miikke] 09/11/2022 12:33

Is there any chance of another company making a bid? It does seem cheap at 115p.

[samewe] 09/11/2022 08:26

They hope that as a private company, it will have a higher valuation if and when they sell the company

[brummy_git] 09/11/2022 08:11

Planned 115p/share tender offer for SourceBio shareholders, before going private.

All the news here

www.linkedin.com/posts/paul-hill-a5994116_sbi-sbi-activity-6996020008975745024-tHGb?utm_source=share&utm_medium=member_desktop

[mr macgregor] 09/11/2022 07:51

Toys out the pram as aim is undervaluing the company - but they'll only pay 115p. What a coque up.

[c3479z] 13/9/2022 14:24

what disturbs is that the CFO gave a summary at the presentation without mentioning, as far as memory serves, that the group made a loss, reinforcing the cherry-picking approach also adopted at the results announcement where readers had to scan down almost towards the end of the announcement before this was disclosed.
Do agree that there is plenty of opportunity in cellular pathology but the idea that a 24 hour turnaround time can be achieved across the board is false- it may be possible for the simplest specimens and biopsies to present digitised images to the pathologist within 24 hours but for more complex cases a period of specimen fixation, dissection, block selection and processing can mean a 4-5 day period between specimen receipt and slides being available,
the overall turnaround time varies with the diligence of the pathologist who must fit in reporting with a number of other commitments,if they work in the NHS also- MDT meetings, post mortems, CPD, specimen dissection...
plenty of competition for private work even if SBI and LD combined are the biggest provider: digitisation of slides not all that novel- it's happening also in the NHS where amalgamations between labs could eventually lead to a more efficient service/increased competition for SBI, with on-site molecular pathology/NGS also becoming standard.
Agree there is a present global shortage of pathologists and increasing demand for cellular path as the population ages, more endoscopies done, skin biopsies and gynae specimens taken and more complex investigations required - seems that cellular path is not a highly popular specialty among medical graduates since pathology was de-emphasised at the medical schools but staffing tends to go in cycles though no present sign of improvement...especially as the NHS London medical staff weighting is not sufficient to prevent staff moving to the provinces once trained up..
Overall therefore outlook should be good for their cellular path division especially if they can integrate it with their genomics outfit.

[samewe] 10/9/2022 07:47

The healthcare diagnostic business, organic and LDpath together as of August is trending with monthly sales of around £1.5 million. The other 2 core businesses are also growing. 2023 will see a very positive performance.

[pldazzle] 10/9/2022 07:37

c3479z - sorry, but that has to be an unduly jaundiced way of putting it. The loss in H1 was substantially due to £2.466m of exceptional expenses, although admittedly a significant part of these related to the PCR/Covid business which, as you say, is declining and is no longer treated as core. As to "waffling on about how wonderful the opportunity is in cellular pathology": In H1/22, sales in the healthcare diagnostics division were £6.823m, including £2.2m from LDPath which was acquired on 8/3/22 - so £4.6m excluding LDPath, compared with £1.658m in H1/21. That's like-for-like growth of 177% - I don't think you can complain. And they mentioned that the growth trend has continued into July and August; plus, LDPath was only in for less than 4 months and has yet to hit its full potential. Moreover, it's clear that the group is expanding due to increased demand, particularly in diagnostics and genomics. "Waffling on"? Surely the numbers speak for themselves?

JLeQ's style may be seen by some as being on the brash side, but overall this was encouraging rather than otherwise.

[c3479z] 09/9/2022 20:10

listened to the presentation, think they could have mentioned the overall loss incurred in H1,due to the declining PCR/Covid business, rather than waffling on about how wonderful the opportunity is in cellular pathology- claim a 24 hour turnround time there but this can only be for the most simple specimens, one suspects.

[jacks13] 08/9/2022 09:31

Not in this market we won't. We'd do well to get through 130p!
I foolishly paid 220p during the Covid frenzy. It'll be a while before we see that although I see that according to Brummy Liberum have a 210p TP, although he doesn't give a timescale. Patience (patients?) needed.

[samewe] 08/9/2022 07:28

Let’s hope we will see some upwards movement on the share price to above 200p.

[brummy_git] 08/9/2022 07:14

Excellent H1 numbers, and positive outlook today from SourceBio's core divisions.

All the details & commentary here

www.linkedin.com/posts/paul-hill-a5994116_sbi-sbi-activity-6973523349662535680-MKpH?utm_source=share&utm_medium=member_desktop

[ptolemy] 01/9/2022 10:38

Half-year results in a week.

Meanwhile, job adverts:

[brummy_git] 06/8/2022 18:28

SBI discussed here at 39:50

www.linkedin.com/posts/paul-hill-a5994116_stocks-to-follow-on-vox-markets-5th-august-activity-6961333951869132800-MOyn?utm_source=linkedin_share&utm_medium=member_desktop_web

[c3479z] 02/8/2022 18:59

histopath extremely labour intensive, though not particularly capital intensive, wonder what the margins will be, becoming more in demand with the ageing population, limited by the number of pathologists and tendency to appoint gastroenterologists gynaecologists and dermatologists who take many biopsies, red tape, CPD, numerous MDT meetings that need to be attended, and will expand to molecular and liquid biopsies in years to come. many hospitals have backlogs that require the likes of source bio to clear.

[brummy_git] 02/8/2022 07:27

Terrific LFL revenue growth from leading laboratory services firm SourcebioPlc today.

All the commentary here.

www.linkedin.com/posts/paul-hill-a5994116_sbi-nhs-activity-6960117009246208000-fyUk?utm_source=linkedin_share&utm_medium=member_desktop_web

[ptolemy] 28/6/2022 14:53

SBI article

[brummy_git] 28/6/2022 14:06

Christopher Mills of Harwood Capital talks about SourceBio here (starts 27;40)

www.linkedin.com/posts/paul-hill-a5994116_vox-markets-fund-manager-interview-with-christopher-activity-6947490289783603200-5DnF?utm_source=linkedin_share&utm_medium=member_desktop_web

hxxps://www.voxmarkets.co.uk/articles/vox-markets-fund-manager-interview-with-christopher-mills-3caf5ae

[brummy_git] 24/6/2022 17:27

Today Justin Waite & I talked about SourceBio here.

hxxps://www.linkedin.com/posts/paul-hill-a5994116_stocks-to-follow-on-vox-markets-24-06-22-activity-6946129824616726528-WCLK?utm_source=linkedin_share&utm_medium=member_desktop_web

hxxps://www.voxmarkets.co.uk/articles/stocks-to-follow-on-vox-markets-24-06-22-8c4d7c9

[brummy_git] 15/6/2022 08:52

Elsewhere within healthcare, Jay Lecoque, Exec Chairman of Sourcebio, takes me through today's positive & in line trading update.

Another great company too.

www.linkedin.com/posts/paul-hill-a5994116_sourcebio-international-qa-with-executive-activity-6942744330864381952-xmfr?utm_source=linkedin_share&utm_medium=member_desktop_web

[brummy_git] 15/6/2022 07:56

Cracking start to the year for medical diagnostics & lab services firm Sourcebio

Find out all the news & commentary here

www.linkedin.com/posts/paul-hill-a5994116_sbi-sbi-activity-6942730919749320705-D-zg?utm_source=linkedin_share&utm_medium=member_desktop_web

[base7] 26/4/2022 11:47

Great to see Lombard Odier increasing their substantial holding further